retatrutide phase 2 trial type 2 diabetes weight loss Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished New GLP-3 drug significantly slashes

The House-version of the annual defense policy bill, which passed out of the chamber this summer, includes a provision that would require the defense secretary to develop a strategy to align the Pentagons obesity-related programs with the classification of obesity as a medically accepted disease

Red or pink urine May indicate blood in urine (hematuria) or food/medication pigments

In 2025, CMS signaled it would allow Medicare Part D and Medicare Advantage plans to optionally cover GLP-1 medications approved for cardiovascular risk reduction which includes semaglutide

Conversely, the first line treatment for IIH, acetazolamide, has little to no effect on weight loss ( Table 2 ) (16)

Triple agonist Retatrutide vs dual agonist Tirzepatide: which works better